Inhibitors of mutant IDH1 have been characterized, such as the recently FDA-approved Vorasidenib [93], a first-in-class dual inhibitor of mutant IDH1 and IDH2 [94] with proven efficacy in IDH-mutant gliomas. The gene discussed is IDH1; the disease is glioma.